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S U M M A R Y
Objectives: We aimed to characterize neurological outcomes and determine the prevalence of HIV
encephalopathy in a cohort of HIV-infected children in Jamaica.
Methods: Data for 287 HIV-infected children presenting between 2002 and 2008 were reviewed and
neurological outcomes characterized. A nested case–control study was conducted between July and
September 2009 used 15 randomly selected encephalopathic HIV-infected children aged 7–10 years and
15 matched controls (non-encephalopathic HIV-infected). Their neurocognitive functions were
evaluated using clinical assessment and standardized tests for intelligence, short term memory
(visuo-spatial and auditory), selective attention, and ﬁne motor and coordination functions. Outcomes
were compared using Fisher’s exact test and the Mann–Whitney U-test.
Results: Sixty-seven (23.3%) children were encephalopathic. The median age at diagnosis of HIV
encephalopathy was 1.6 years (interquartile range (IQR) 1.1–3.4 years). Predominant abnormalities
were delayed milestones (59, 88.1%), hyperreﬂexia (59, 86.5%), spasticity (50, 74.6%), microcephaly (42,
61.7%), and quadriparesis (21, 31.3%). The median age of tested children was 8.7 years (IQR 7.6–10.8
years) in the encephalopathic group and 9 years (IQR 7.4–10.7 years) in the non-encephalopathic group.
Encephalopathic children performed worse in all domains of neurocognitive function (p < 0.05).
Conclusions: A high prevalence of HIV encephalopathy was noted, and signiﬁcant neurocognitive
dysfunction identiﬁed in encephalopathic children. Optimized management through the early
identiﬁcation of neurological impairment and implementation of appropriate interventions is
recommended to improve quality of life.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Jamaica, a middle-income developing country in the Caribbean
with a gross national income per capita of US $5020, has an HIV
seroprevalence of 1.7%.1,2 In 2002, the Kingston Paediatric and
Perinatal HIV/AIDS Program (KPAIDS) was established as a
multidisciplinary collaboration between the Elizabeth Glaser
Pediatric AIDS and Pﬁzer Foundations, the University of the West
Indies, Mona, and the Jamaica Ministry of Health.3,4 The primary
focus of the program has been the prevention of mother-to-child
transmission (MTCT), while improving the quality of life of infected
children and adolescents.3,4 Since its inception, great progress has
been made in the characterization and management of infected§ Presented in part as an oral platform presentation at the XVIII International HIV/
AIDS Conference, Vienna, Austria, July 2010. Abstract MOAB0401.
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http://dx.doi.org/10.1016/j.ijid.2013.02.014children, including clinicopathologic ﬁndings, outcomes of antire-
troviral therapy (ART), and adherence.3,4
One of the most deleterious complications of pediatric HIV
disease is HIV-associated neurological disease. Since the beginning
of the pandemic, with continuing advances in the development
and increased use of ART, there has been a noticeable reduction in
the prevalence of HIV-associated neurological disease in developed
countries, from 50–60% to 13–23%.5–7 In the developing world,
there is still a relatively high prevalence of neurological disease
associated with pediatric HIV disease. Neurological disease is three
times more common in children than adults, and is often the initial
presentation of HIV disease, with 75% of cases occurring within the
ﬁrst 2 years of life.8–15
The majority of children with HIV-associated neurological
disease are infected by maternal–fetal transmission. Through this
route, there is an increased risk of irreversible brain damage,
including cerebral atrophy, intracerebral calciﬁcations, and mi-
crocephaly, as well as various degrees of developmental delay and
cognitive impairment.16,17 The most common and the most well
described form of HIV-associated neurological disease in childrenses. Published by Elsevier Ltd. All rights reserved.
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achieve appropriate developmental milestones, impaired brain
growth, and global or selective impairments in cognitive, language,
motor, attention, behavior, and social skills that may affect day-to-
day functioning. With latency to HIV encephalopathy ranging from
2 months to 5 years, some of these children may rapidly progress to
death, while others may experience intermittent periods of
stability interspersed with periods of deterioration.
HIV is neurotropic. Early in the course of HIV infection, a rapid
rate of productive central nervous system (CNS) viral replication
occurs, which leads to early manifestations of neurologic disease.
These neurologic manifestations can occur before immune
suppression by the virus,10 and are sometimes used as clinical
indicators of HIV infection. Highly active antiretroviral therapy
(HAART) has been shown to suppress viral replication, improve
immune function, and decrease the likelihood of AIDS-related
death. It has also been shown to improve neurological functioning
in children affected by HIV encephalopathy.18,19
With a dearth of existing data for developing countries in
general, and for the Caribbean in particular, we aimed to describe
the neurological outcomes of HIV-infected children in Jamaica and
determine their neurocognitive function.
2. Methods
2.1. Setting and participants
The medical records of infected children and adolescents (aged
0–18 years) enrolled in four KPAIDS clinics in the Greater Kingston
Metropolitan area between September 2002 and August 2008 were
reviewed. Three hundred thirty-six children were enrolled during
the study period. Their serostatus was conﬁrmed by HIV DNA PCR
(Roche) and/or HIV ELISA (EIA/Rapid Determine) with conﬁrmato-
ry Western blot at the point of enrolment during the period of
study. Follow-up care was facilitated by healthcare personnel
trained in pediatric ambulatory management and using uniﬁed
management protocols, facilitated access to care, and implemen-
tation of monitoring and evaluation mechanisms.4
2.2. Measurements
2.2.1. Neurological characterization: medical database review
Demographic data, clinical neurological characteristics, immu-
nologic and virologic indices at diagnosis of HIV infection, and HIV
encephalopathy were retrospectively collated from a secure client
management database4,5 and validated through a review of the
medical records. Clinical ﬁndings congruent with the US Centers
for Disease Control and Prevention (CDC) criteria for HIV
encephalopathy were also identiﬁed.20
CDC criteria for HIV encephalopathy require at least one of the
following to have been present for the past 2 months in the absence
of a concurrent illness other than HIV infection that could explain
the ﬁndings: (1) loss of previously acquired skills, (2) signiﬁcant
drop in cognitive test scores, generally to the borderline/delayed
range, with functional deﬁcits (deﬁcits in day-to-day functioning),
(3) cognitive test scores in the borderline/delayed range, with
functional deﬁcits (and no history of signiﬁcant drop or previous
testing available), (4) signiﬁcantly abnormal neurologic exam with
functional deﬁcits (i.e., signiﬁcant tone, reﬂex, cerebellar, gait, or
movement abnormalities), (5) signiﬁcant improvement in cogni-
tive test scores over approximately a 6-month period associated
with a new treatment when baseline scores are in the borderline to
delayed range (no history of previous testing), with or without
signiﬁcant brain imaging or neurologic abnormalities.
Record reviews of all 287 infected children were used to
determine the prevalence of neurological characteristics for theentire cohort. The initial time of HIV diagnosis, start of HAART, and
the end of the study time period were used as the time points of
review for the entire cohort. Additionally, two other time points
were used for determining the prevalence of neurological deﬁcits
in encephalopathic children (at initiation of HAART and 12 months
post-start of HAART). HAART was deﬁned as an antiretroviral drug
treatment plan in which two nucleoside reverse transcriptase
inhibitors were administered in conjunction with a non-nucleo-
side reverse transcriptase inhibitor or a protease inhibitor.20
2.2.2. Neurocognitive evaluation
Using a nested case–control cohort design, we randomly
selected a group of 15 encephalopathic children, aged 7–10 years,
from our cohort. They were matched by age, sex, education, type of
caregiver (family or government institution), and ART use with
infected, non-encephalopathic controls (n = 15) with CDC category
N, A, or B disease21 from our cohort. The median duration of HAART
use in the encephalopathic group was 5.5 years (interquartile
range (IQR) 4.8–7.5 years), as compared to 2.3 years (IQR 0–5.3
years) for the non-encephalopathic group.
2.3. Questionnaire and clinical examination
Validated questionnaires were used to determine demographic,
socioeconomic, and educational backgrounds of the children and
their caregivers.22 Clinical neurological examinations were per-
formed by pediatricians. The primary investigators were blinded to
the results of the examinations.
2.4. Neurocognitive testing
Several tests were used to assess the children’s cognitive and
motor functions. These tests were chosen by a child development
specialist as they had previously been used in several studies in
Jamaica and had shown differences between nutritionally deprived
and well nourished children from similar backgrounds.23,24 The
tests were administered using Standard English (UK), the native
language of Jamaica.
The tests administered assessed: (1) Intelligence: general
intelligence was measured with Raven’s Coloured Progressive
Matrices. Participants were asked to ﬁnd the missing pattern from
a series of options, with each successive set of items becoming
more challenging. With increasing levels of difﬁculty, the
analytical skills of the child were assessed.25,26 Full intelligence
quotients (IQ) were not determined. (2) Memory: visuo-spatial
memory was assessed with the Corsi Block test (Milner and Corsi,
1972). In this test, children were asked to reproduce various
sequences that blocks were pointed at.27 Auditory memory was
measured with Digit Span Forward from the Wechsler Intelligence
Scale for Children fourth edition (WISC-IV). In this test, partici-
pants were asked to repeat various sequences of random numbers
read aloud to them.28,29 (3) Attention: Map Mission Search, a
subtest from the Test of Everyday Attention for Children, TEA-
Ch30,31 was used to measure selective attention. In this test,
children were asked to ﬁnd as many pictures of an object shown to
them on a map. The total number of pictures found within a minute
was recorded. (4) Fine motor and coordination:32–36 (a) posting
coins (subtest of the Movement Assessment Battery for Children,
1992) required the children to place a selected number of coins in
an enclosed box as quickly as they could. The average time taken to
complete the task twice was recorded; (b) the grooved pegboard
test (Matthews and Klove, 1964) required the children to place
grooved pegs into slots on a metal board. The average time taken to
complete the task was recorded; (c) the hand pronation–
supination test (Physical and Neurological Assessment of Subtle
Signs; Denckla, 1985) required that children rapidly rotate their
Table 1
Neurological abnormalities (from database review) in encephalopathic (n = 67) and





Delayed milestones 59 (88.1) 10 (0.05)
Hyperreﬂexia 58 (86.5) 20 (0.1)
Spasticity 50 (74.6) -
Microcephaly 42 (61.7) 5 (0.02)
Quadriparesis 21 (31.3) -
Milestone regression 15 (22.4) -
Poor learning 14 (20.9) 30 (0.14)
Ataxia 10 (14.9) -
Diplegia 10 (14.9) -
Hemiplegia 4 -
Poor behavior 4 -
Poor coordination 1 -
Table 2
Neurological abnormalities at initiation and 12 months after start of HAART in
children with HIV encephalopathy (n = 64)




Hyperreﬂexia 55 (86.0) 49 (76.6)
Delayed milestones 53 (82.9) 45 (70.4)
Spasticity 45 (70.3) 41 (64.1)
Microcephaly 37 (57.8) 37 (57.8)
Quadriparesis 16 (25.0) 13 (20.4)
Milestone regression 13 (20.3) 9 (14.1)
Poor learning 13 (20.3) 18 (28.1)
Ataxia 11 (17.2) 20 (31.3)
Diplegia 10 (15.6) 13 (20.4)
Hemiplegia 4 (6.3) 4 (6.3)
Poor behavior 3 (4.7) 3 (4.7)
Poor coordination 1 (1.6) 1 (1.6)
HAART, highly active antiretroviral therapy.
a By paired t-test, all p > 0.05.
S.Y. Walker et al. / International Journal of Infectious Diseases 17 (2013) e862–e867e864forearms. The average time taken to complete two sets of 20
rotations was recorded.
For all of these timed tests, lower scores indicated faster times
taken to complete the test.
Inter-observer reliabilities (r) were established for all tests
before the study began using HIV-negative children (n = 7), and
all were greater than 0.97. These reliabilities were obtained by
comparisons of examiner scores for all tests, where observers
watched each other during testing of each HIV-negative
child.
Between July and September 2009, the children were each
tested during a single session at their respective clinics. Test
administration required 2 h to complete. Each test was individu-
ally scored, with the results compiled and tabulated.
2.5. Statistical analysis
Demographic data were summarized and compared with those
of controls using Fisher’s exact test and the Mann–Whitney U-test.
The change in prevalence of neurological characteristics at 12
months post-HAART was compared with baseline ﬁndings using a
paired t-test. Clinical ﬁndings from the nested case–control study
were compared with the Mann–Whitney U-test. The raw scores of
the neurocognitive testing were also compared using the Mann–
Whitney U-test. The cognitive scores and time taken to complete
ﬁne motor tasks were compared using the Mann–Whitney U-test.
Data were analyzed with the Statistical Program for Social Sciences
version 12.0 (SPSS Inc., Chicago, IL, USA).
2.6. Ethics statement
Ethical approval was received from the University Hospital of
the West Indies/University of the West Indies Faculty of Medical
Sciences Ethics Committee. Informed consent was obtained from
primary caregivers, and assent from infected children who were
aware of their HIV status (>8 years of age).
3. Results
3.1. Demographics
Three hundred thirty-six children were enrolled in the KPAIDS
program between September 2002 and August 2008. Twenty-six
medical records were missing, and 23 children were lost to follow-
up less than 1 year after enrolment. The medical records of 287
children were subsequently reviewed. The record review reporting
points for encephalopathic children were at initial diagnosis of HIV,
diagnosis of HIV encephalopathy, initiation of HAART, and 12
months post-start of HAART. For non-encephalopathic children the
reporting points were at initial diagnosis of HIV, initiation of
HAART, and at the end of the study period.
Just over half (53.3%; 153/287) of the cohort was female. MTCT
was the most common mode of infection in our cohort, accounting
for 89.9% (258/287) of cases.
3.2. Neurological characteristics
Sixty-seven (23.3%) children were diagnosed with HIV enceph-
alopathy, with 88.1% (57/67) being diagnosed at less than 5 years
of age. The median age at diagnosis was 1.6 years (IQR 1.1–3.4
years). The common neurological deﬁcits identiﬁed on diagnosis of
HIV encephalopathy (Table 1) were delayed milestones (59, 88.1%),
hyperreﬂexia (58, 86.5%), spasticity (50, 74.6%), microcephaly (42,
61.7%), and quadriparesis (21, 31.3%).
Of non-encephalopathic children, 15.5% (34/220) had other
neurological deﬁcits, including learning deﬁcits (reading andbasic arithmetic), delayed milestones, isolated hyperreﬂexia,
isolated microcephaly, and progressive multifocal leukoence-
phalopathy. These clinical ﬁndings were not congruent wit
CDC criteria for HIV encephalopathy, as they were either
isolated clinical ﬁndings or had been present for less than
2 months.
Sixty-four (95.5%) were started on HAART. The majority of these
children (60/64) started HAART after they were diagnosed with
HIV encephalopathy, with the median time to start HAART of 22
days (IQR 0–92 days). There was a small reduction in the
prevalence of neurological deﬁcits at 12 months post-HAART
(Table 2), although not statistically signiﬁcant (p > 0.05).
3.3. Neurocognitive evaluation
The median age of tested children was 8.7 years (IQR 7.6–10.8
years) in the encephalopathic group and 9 years (IQR 7.4–10.7
years) in the non-encephalopathic group. The encephalopathic
group achieved lower test scores than their non-encephalopath-
ic peers in the Raven’s Progressive Coloured Matrices. Addition-
ally, they achieved lower test scores in the Corsi Block, Digit
Span, and Map Search tests. They also took longer times to
complete the motor tests – the grooved pegboard, posting coins,
and the hand pronation–supination tests (Table 3). Two
encephalopathic children were unable to complete the grooved
pegboard test due to signiﬁcant motor impairment; they were
severely spastic.
Table 3
Median (range) cognitive and motor test scores for encephalopathic (n = 15) and non-encephalopathic (n = 15) children
Variables Encephalopathic
Median raw scores (range)
Non-encephalopathic
Median raw scores (range)
p-Valuea
Intelligence
Raven’s Matrices (score) 13 (5–19) 18 (9–30) 0.006
Memory
Corsi Blocks (score) 5 (1–8) 8 (3–11) 0.001
Digit Span (score) 5 (1–9) 8 (3–12) 0.012
Attention
Map Search (score) 15 (1–36) 23 (10–47) 0.024
Motor/coordinationb
Posting coins: dominant hand (s) 20.6 (14.9–40.8) 17.1 (12.2–24.4) 0.020
Posting coins: non-dominant (s) 25.5 (16.9–48.3) 19.2 (13.8–27.6) 0.024
Grooved pegboard: dominant (s)c 62.1 (40.8–300.0) 46.8 (33.0–113.0) 0.007
Grooved pegboard: non-dominant (s)c 82.0 (56.2–300.0) 60.8 (39.0–93.3) 0.004
Hand movement: dominant (s) 16.9 (12.5–31.8) 13.9 (10.2–28.7) 0.062
Hand movement: non-dominant (s) 19.3 (14.0–33.4) 15.3 (10.9–22.8) 0.006
a Mann–Whitney U-test.
b Lower test scores indicate faster times.
c n = 13, encephalopathic group.
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This is the ﬁrst comprehensive characterization of neurocog-
nitive function among HIV-infected children in the Caribbean. Our
prevalence of 23.3% of HIV encephalopathy concurs with
international data from developed countries,8–10 with prevalence
data of 16–35%. The median age at diagnosis of encephalopathy
was 1.6 years (IQR 1.1–3.4 years). This age is congruent with the
period when deﬁcits in major developmental milestones such as
walking, talking, and basic communication skills become more
noticeable. Schanbhag et al. noted a similar age in a North
American cohort (1.75 years, range 0.33–9.33 years).37 MTCT was
the main mode of transmission in encephalopathic children
(95.5%; compared to 88.2% in non-encephalopathic children). This
is similar to the results of international studies that have shown
MTCT to be the main mode of transmission in encephalopathic
children.8,12,14,15 MTCT is an important factor in the development
of pediatric CNS disease. In the presence of elevated HIV viral load,
the young developing brain will suffer signiﬁcant insults both
ante- and post-partum leading to the varied manifestations that
have been shown to occur in HIV encephalopathy.
Despite the widespread use of HAART (95.5%), there was only a
small reduction in the prevalence of neurological deﬁcits at 1 year
post-HAART in our cohort. Smith et al.38 also showed that the
prevalence and severity of neurological deﬁcits did not signiﬁ-
cantly improve at 6 months post-HAART in a South African cohort.
Postulated reasons include host factors (e.g., age <15 years,
polymorphisms of receptors leading to increased chemokine
release) and viral factors (e.g., emergence of resistant genotypes
in the CNS).39,40 Variable ART penetration and early viral
sequestration in the developing brain may also impact on the
efﬁcacy of treatment of pediatric CNS disease.41,42 HAART
primarily works to prevent further HIV replication and reduce
the progression of HIV-induced cellular damage. By delaying the
use of HAART, profound irreversible inﬂammatory changes will
occur. So, although there may be a virological and immunological
response to the use of HAART, severe irreversible neurocognitive
deﬁcits may be present. This possibly explains the unfavorable
neurological outcome despite a median time of 22 days to the start
HAART after diagnosis of HIV encephalopathy. Additionally,
routine pediatric HIV care and prevention strategies in Jamaica
were not introduced until 2002, and universal access to HAART
occurred in 2005. With a lag in prevention of vertical transmission
strategies compounded by inadequate access to HAART, the rate of
deterioration of our encephalopathic children would havesurpassed that of children in the developed world. Thus, late
initiation of HAART in our children would not have been able to
address the deleterious effects of advanced neurological inﬂam-
mation and damage that occurs as a result of pediatric HIV disease.
Our data show an abnormal neurocognitive proﬁle for the
encephalopathic group. Despite similar socioeconomic and educa-
tional backgrounds, their performance in all of the cognitive and
motor tests was signiﬁcantly below that of their non-encephalo-
pathic peers. The encephalopathic group achieved signiﬁcantly
lower scores for tests of general intelligence, memory, and
selective attention. They were slower in all tests of motor function
and coordination. These differences may not only be explained by
motor impairments, but also by deﬁcits in visuo-spatial memory
and processing speed in encephalopathic children. Our results
mirror the experience of others in the developed world,42,43 who
have reported signiﬁcant impairment in visuo-spatial function and
attention in HIV-infected children when compared to non-infected
peers. With the absence of normal, non-infected children in our
study, there is the possibility that infected non-encephalopathic
children may already have various unrecognized neurocognitive
deﬁcits.
There was the possibility of inter-observer bias associated with
the assessment and documentation of neurological ﬁndings with
longitudinal follow-up of the cohort. However, the use of uniﬁed
management protocols and supervision by senior pediatricians
served to decrease this limitation. The use of trained investigators
and pediatricians to conduct neurocognitive testing and neurolog-
ical examinations strengthened the validity of the ﬁndings. Some
statistically insigniﬁcant ﬁndings in our case–control study may
have been due to low statistical power (n = 30).
Although we used few tests of development on a relatively
small sample, we were able to show signiﬁcant effects of HIV
encephalopathy in this cohort. Longitudinal data regarding
cognitive performance of the cohort are needed, but due to
limitations in ﬁnancial resources and time, we were unable to
conduct formal cognitive evaluations. Formal IQ data (relating to
scholastic achievement) and behaviors are also important areas of
development that were not explored in this study, and would be
very useful in providing a better perspective on the overall function
of these children.
In conclusion, this study highlights the importance of evaluat-
ing neurocognitive outcomes in HIV-infected children, particularly
those with HIV encephalopathy. One cannot underestimate the
impact of strengthening MTCT prevention strategies and early
infant diagnosis in reducing the frequency and severity of pediatric
S.Y. Walker et al. / International Journal of Infectious Diseases 17 (2013) e862–e867e866HIV infection. Additionally, initiation of HAART for all infants
less than 12 months of age18,44 is likely to mitigate the
deleterious viral effects on the developing brain.43 This has
already been conﬁrmed by the CHER study.45 Violari et al.
showed the beneﬁts of early HAART administration in infected
children in preventing rapid disease progression. Our study
suggests the need for judicious and early administration of
HAART for the prevention of severe neurological morbidity. Van
Rie et al.46 demonstrated the beneﬁt of early HAART in
neurodevelopmental outcomes for these children. In a 1-year
period, the motor skills of infected children aged less than 3
years improved with the early administration of HAART and
judicious management protocols.
In addition to early diagnosis, treatment, and timely follow-up,
measures to increase access to standard neurocognitive tests (as
cost-effective screening tools) will promote early identiﬁcation of
neurocognitive dysfunction and enable implementation of tar-
geted interventions such as physical, occupational, and speech
therapies. Collectively, these strategies will contribute towards
improving the quality of life of these children, while enabling them
to make purposeful contributions to society as they transition
through adolescence to adulthood.
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